Euronews is no longer accessible on Internet Explorer. This browser is not updated by Microsoft and does not support the last technical evolutions. We encourage you to use another browser, such as Edge, Safari, Google Chrome or Mozilla Firefox.
BREAKING NEWS

Roche's Tecentriq wins speedy U.S. review in small cell lung cancer

Roche's Tecentriq wins speedy U.S. review in small cell lung cancer
FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann -
Copyright
ARND WIEGMANN(Reuters)
Euronews logo
Text size Aa Aa

ZURICH (Reuters) - Roche's <ROG.S> Tecentriq immunotherapy with chemotherapy won priority review in the United States for the initial treatment of extensive-stage small cell lung cancer (SCLC), the company said, setting up possible approval by March 18.

Wednesday's announcement comes after Roche in September said patients with untreated extensive-stage SCLC, where cancer has spread, lived a median 12.3 months after getting Tecentriq plus chemotherapy, compared to 10.3 months for those on just chemotherapy.

(Reporting by John Miller; editing by Thomas Seythal)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.